PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG.\', \'Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia.\', \'Department of Microbiology and Immunology, The University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia.\', \'Viral Immunology and Respiratory Disease group and Priority Research Centre for Healthy Lungs, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.\', \'Ena Respiratory, Level 9, 31 Queen St, Melbourne, Victoria, 3000, Australia. Electronic address: fm@enarespiratory.com.\', \'National Infection Service, Public Health England (PHE), Porton Down, Salisbury, Wiltshire, United Kingdom SP4 0JG; Nuffield Dept of Medicine, Oxford University, Oxford, UK. Electronic address: miles.carroll@phe.gov.uk.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2352-3964(20)30529-610.1016/j.ebiom.2020.103153
?:doi
?:hasPublicationType
?:journal
  • EBioMedicine
is ?:pmid of
?:pmid
?:pmid
  • 33279857
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.895
?:rankingScore_hIndex
  • 26
is ?:relation_isRelatedTo_publication of
?:title
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33279857>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33279857>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all